Trans Genic GroupTRANS GENIC GROUP INC.2342東証スタンダードサービス業FY ending Mar 2026, consolidated, J-GAAP

Trans Genic Group FY ending Mar 2020 results

About 43% of Trans Genic Group's sales come from TGBS Business, with E-commerce business and Others making up much of the rest.

Out of every ¥100 of sales, about ¥2 is left as operating profit.

Where the money goes

※ Segment revenues include inter-segment sales and are scaled to consolidated revenue

For every ¥100 Trans Genic Group sells, how much goes where, and how much is kept.

FY ending Mar 2020

Margin funnel (derived from reported values)Gross margin 16.1% → Operating margin 1.6% → Net margin -4.0%

Revenue by business segment, and the profit each one keeps.

FY ending Mar 2020

TGBS Business¥8.25B
43%
Op. margin 4.5%
E-commerce business¥5.33B
28%
Op. margin 1.5%
Others¥2.92B
15%
Op. margin 9.8%
Drug discovery support business¥2.8B
14%
Op. margin -0.4%Industry: CRO & Clinical Testing

※ Segment figures include inter-segment sales and do not sum to the company total

Show source documents (3)

EDINET (FSA Japan)
有価証券報告書－第26期(2023/04/01－2024/03/31)
ID S100TPLD2024-06-21Open
EDINET (FSA Japan)
有価証券報告書－第24期(令和3年4月1日－令和4年3月31日)
ID S100OEUK2022-06-24Open
EDINET (FSA Japan)
有価証券報告書－第23期(令和2年4月1日－令和3年3月31日)
ID S100LOBQ2021-06-24Open

Extracted from XBRL: 43 / Derived from other figures: 2

Spotted an error? Report it (corrections keep the original record)

Markdown with figures, units, periods and sources, ready to paste into ChatGPT or Claude.